The firm missed analysts' consensus estimate for the quarter, but its revenues were in line with its guidance of between $275 million and $290 million. For full-year 2010, its revenues were up 8 percent.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.